Advertise with NationWire
728 × 90 Leaderboard
Advertise Here
Science

FDA Approves Lembaz, First Drug Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease

Advertise with NationWire
300 × 250 Medium Rectangle
Advertise Here

The US Food and Drug Administration has approved Lembaz, the first treatment shown to help people with a severe form of Niemann-Pick disease type C live longer.

The decision, announced on 17 November, covers adults and children who weigh at least 7 kilograms — about 15 pounds — and whose neurological symptoms began before the age of six. That form of the illness is known as infantile-onset Niemann-Pick disease type C, or I-NPC.

Niemann-Pick disease type C is a rare, progressive and ultimately fatal disorder in which cholesterol and other fats build up inside cells, damaging the brain and other organs. Children with the infantile-onset form develop neurological symptoms early in life, and most do not survive into adulthood. Until now, no medicine had been shown to extend survival in this group.

What the approval covers

Lembaz, known by its generic name adrabetadex, is approved to reduce the risk of death in patients with I-NPC. It is given by injection into the fluid around the spinal cord, known as intrathecal injection, once every two weeks.

The approval applies to patients weighing at least 7 kilograms with neurological symptoms that began before six years of age. The drug is made by Beren Therapeutics, and the FDA granted the approval to Mandos, a subsidiary of the company.

Lembaz is also the first medicine approved that addresses the underlying cholesterol-trafficking defect behind the disease, rather than only managing its symptoms. An earlier treatment for Niemann-Pick disease type C was approved in September 2024, but it was not shown to extend survival.

The survival evidence

The approval rests on an analysis of overall survival in 36 patients with infantile-onset disease who received adrabetadex across three clinical studies and an expanded access programme, compared with a matched external control group. The FDA said in its announcement that it regarded that comparison as the adequate and well-controlled study supporting approval.

Treatment was associated with a 55 per cent reduction in the risk of death. Median survival was 8.5 years among treated patients, compared with 4.9 years among the matched controls. The benefit was seen whether or not patients were also taking miglustat, a drug used off-label in the disease.

An earlier survival analysis, presented in March 2026, pointed in the same direction. It compared 72 treated children with 119 matched controls and reported a 71 per cent lower risk of death, with five-year survival of 84 per cent against 42 per cent.

The evidence base has limits that the agency and the company acknowledge. The approval was not based on a randomised trial. The only randomised trial of the drug lasted 12 months, and its results led the FDA to rescind the drug’s first Breakthrough Therapy designation, granted in 2016 under a previous sponsor. The designation was granted again in 2025.

A serious hearing warning

Lembaz carries a boxed warning — the FDA’s strongest — for hearing impairment, including permanent hearing loss. The warning applies even to patients whose hearing was normal before treatment, and hearing loss in some patients has ranged from mild to profound.

Because of that risk, patients need hearing tests before treatment begins and repeated audiology evaluations afterwards, with doses adjusted in line with the results. Ataxia and fatigue can also follow each dose.

How the drug works

Adrabetadex is a mixture of cyclodextrin compounds, a form of 2-hydroxypropyl-beta-cyclodextrin. It is designed to mobilise cholesterol trapped inside cells, compensating for the faulty NPC proteins that cause the disease.

In the disease, mutations in the NPC1 or NPC2 genes stop cells moving cholesterol properly, and the build-up damages the brain, liver and spleen.

By helping trapped cholesterol move again, the drug targets the mechanism of the disease itself. That is what sets it apart from earlier approaches, which focused on easing symptoms.

What happens next

Beren Therapeutics said the drug will be available at treatment sites across the United States in early December, with a family access programme offering help with site coordination and out-of-pocket costs for eligible patients.

The company also received a Priority Review Voucher with the approval.

The approval arrives in a busy period for the agency’s work on children’s health. It follows the agency’s fast-track designation for a children’s insomnia drug earlier this month, and comes in the same week that the United States lost its measles elimination status after more than a quarter of a century.

For the small community of families affected by infantile-onset Niemann-Pick disease type C, the decision is the first to offer something previous treatments could not: more time.

Advertise with NationWire
320 × 50 Mobile Banner
Advertise Here

Leave a Reply

Your email address will not be published. Required fields are marked *